Published in Lab Business Week, January 30th, 2005
Under the terms of the financing, Aradigm will sell approximately 8.3 million shares of common stock at $1.50 per share, representing a 16% discount to the closing price on the commitment date.
Gross net proceeds will be $11.75 million. Use of proceeds will include advancement of the company's R&D efforts, working capital and general operations. SG Cowen served as lead placement agent and Punk Ziegel served as co-agent for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.